Ten radiopharmacies are currently in operation, with three more expected to become active shortly. are now delivering more than 120 patient-ready doses of NETSPOT ® in injection form per month. AAA and its radiopharmacy partners around the U.S. NETSPOT ® is available in two forms: As a drug kit for reconstitution using a Ga 68 generator, and as a ready-to-use injection delivered from local radiopharmacies in select metropolitan areas. The product has been used and paid for over the past six months, even prior to the issuance of this Pass-Through code, demonstrating recognition of NETSPOT’s ® value to NET patient management. Food and Drug Administration (“FDA”) in June 2016 for the preparation of gallium Ga 68 dotatate for injection, for the localization of somatostatin receptor positive neuroendocrine tumors (“NETs”) in adult and pediatric patients using Positron Emission Tomography (“PET’).Ī first-in-class drug, NETSPOT ® was approved after a record-breaking 23 months from the first pre-Investigational New Drug meeting with the FDA. Additionally, the same Healthcare Common Procedure Coding System (“HCPCS”) “A Code” will be used on claims to private payers. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (“MNM”), today announced that the Centers for Medicare & Medicaid Services (CMS) has granted NETSPOT ® Transitional Pass-Through status under an “A-code” (A9587) for drug reimbursement, effective January 1, 2017. 08, 2016 (GLOBE NEWSWIRE) - Advanced Accelerator Applications S.A.
0 kommentar(er)
